Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

ABSTRACT: Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

PROVIDER: PRJNA450466 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7012320.fastq.gz	Fastqsanger.gz
	SRR7012321.fastq.gz	Fastqsanger.gz
	SRR7012322.fastq.gz	Fastqsanger.gz
	SRR7012323.fastq.gz	Fastqsanger.gz
	SRR7012314.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 15

Similar Datasets

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

Project description:We used a CRISPR-based screening approach to identify functional vulnerabilities in pediatric sarcoma cell types, identifying BRD9 as an important dependency in synovial sarcoma cells.

2018-11-01 | GSE113228 | GEO

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [RNA-seq]

2018-11-01 | GSE113227 | GEO

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

Project description:Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

| PRJNA450475 | ENA

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

Project description:Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma [ChIP-seq]

| PRJNA450476 | ENA

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.

Project description: Not available

| S-EPMC6277197 | biostudies-literature

ATAC-seq of synovial sarcoma cell lines treated with the BRD9 PROTAC degrader WA-68

Project description:Synovial sarcoma (SyS) is driven by the SS18::SSX fusion oncoprotein, which incorporates into GBAF chromatin remodeling complexes and creates a dependency on BRD9. To investigate the effects of BRD9 loss, we performed ChIP-seq, ATAC-seq, and RNA-seq in SyS models following BRD9 degradation. ChIP-seq shows reduced GBAF occupancy at target loci, while ATAC-seq reveals maintained or increased chromatin accessibility. RNA-seq demonstrates sustained or elevated expression of target genes. These results indicate that BRD9 is not required for GBAF assembly but instead restrains its remodeling activity, providing a mechanistic explanation for the limited efficacy of BRD9-targeted therapies in SyS.

2026-06-24 | GSE328410 | GEO